CRISPR

1. Biological origin and essential components

CRISPR originated as an adaptive defence mechanism in bacteria and archaea against invading genetic material, including bacteriophages and plasmids. A microbial CRISPR locus contains repeated DNA sequences separated by variable spacers. Many spacers originate from earlier invaders and act as a molecular record of infection. During a subsequent encounter, RNA produced from these sequences guides Cas proteins towards matching foreign genetic material, which can then be destroyed.

Scientists adapted this natural recognition system into a programmable laboratory tool. In the widely used CRISPR-Cas9 system, the principal components are a Cas9 nuclease and a guide RNA. The engineered single-guide RNA combines the targeting role of CRISPR RNA with the structural role of trans-activating CRISPR RNA. Changing the guide sequence allows researchers to redirect the same protein towards different genomic sites.

Cas9 also requires an appropriate protospacer adjacent motif, or PAM, beside the target sequence. The commonly used Cas9 from Streptococcus pyogenes usually recognises an NGG PAM, where N represents any DNA nucleotide. PAM requirements differ among CRISPR enzymes. For examinations, distinguish the components clearly: the guide RNA provides sequence recognition, Cas9 cuts DNA, and the cell's repair machinery largely determines the resulting edit.

2. How editing works and why outcomes differ

Researchers first identify a target sequence and design a complementary guide RNA. Cas9 and the guide are introduced into cells as DNA constructs, RNA, or preassembled ribonucleoprotein complexes. After recognising the PAM and pairing with the target, Cas9 generally creates a double-strand break. CRISPR therefore provides a targeted starting point, not an automatic guarantee that the desired genetic change will occur.

Cells commonly repair the break through non-homologous end joining. This pathway can generate small insertions or deletions, called indels, which may disrupt a gene's reading frame and produce a functional knockout. Homology-directed repair can instead use a supplied donor template to introduce a specified sequence change. However, its efficiency depends on cell type and cell-cycle stage, and it is often difficult in non-dividing cells.

Somatic editing alters non-reproductive cells and is not ordinarily inherited by children. Germline or embryo editing can produce heritable changes if the edited cells contribute to reproduction. Ex vivo editing involves removing cells, modifying them outside the body, checking them and returning them to the patient. In vivo editing delivers the editing components directly into the body. Both approaches face delivery constraints, possible immune reactions and requirements for long-term safety assessment.

Unintended outcomes include off-target editing at similar sequences elsewhere in the genome and unwanted on-target changes, such as large deletions or rearrangements. Mosaicism occurs when different cells contain different edits. Consequently, successful targeting must be followed by sequence verification and assessment of biological function; precision of targeting does not mean absence of risk.

3. Beyond conventional Cas9: newer tools and applications

CRISPR describes a technological family rather than a single enzyme. Cas12 systems target DNA and have different targeting and cleavage properties from Cas9. Cas13 targets RNA and can be used for transient manipulation of gene expression. Catalytically inactive Cas9, called dCas9, can bind DNA without cutting it; when linked to regulatory proteins, it can repress or activate transcription.

Base editors couple a targeting protein with an enzyme that converts particular bases, such as C to T or A to G, usually without creating a double-strand break. Prime editing uses a modified Cas9 nickase, reverse transcriptase and a prime-editing guide RNA to install specified substitutions and small insertions or deletions. These tools broaden the range of possible edits but still have efficiency, delivery and unintended-editing limitations.

Applications include studying gene function, creating disease models, identifying drug targets and developing treatments for selected genetic disorders and cancers. Agricultural uses include resistance to pathogens, improved nutritional composition and tolerance to environmental stresses. An edited trait still requires field evaluation: changing one gene cannot automatically solve complex problems such as drought resilience or yield stability.

CRISPR-based diagnostics exploit target recognition and, in some systems, collateral cleavage of reporter molecules. SHERLOCK commonly uses Cas13, while DETECTR commonly uses Cas12. A diagnostic detects a nucleic-acid sequence; it does not necessarily edit the patient's genome. CRISPR-enabled gene drives seek to bias inheritance and spread a trait through a population, but their ecological effects and possible transboundary spread require particular caution.

4. Indian regulation and biotechnology policy

India's biosafety framework includes the Environment (Protection) Act, 1986 and the Rules, 1989 governing hazardous microorganisms and genetically engineered organisms or cells. Institutions such as Institutional Biosafety Committees, the Review Committee on Genetic Manipulation and the Genetic Engineering Appraisal Committee have distinct responsibilities. The relevant pathway depends on the organism, product, application and nature of the modification.

In March 2022, the Ministry of Environment, Forest and Climate Change exempted genome-edited plants in the SDN-1 and SDN-2 categories that are free from exogenous introduced DNA from Rules 7–11 of the Rules, 1989. The Department of Biotechnology subsequently issued guidelines for the safety assessment of genome-edited plants. This was a defined exemption, not a blanket removal of all oversight over genome editing.

Site-directed nuclease categories describe editing outcomes. SDN-1 generally involves repair without a donor template, often creating small mutations. SDN-2 uses a repair template for a predetermined small change. SDN-3 involves insertion of a larger DNA sequence. CRISPR is a tool that can generate different categories; CRISPR and SDN-1 are not synonyms. Human therapeutic applications separately require applicable drug regulation, clinical-trial permissions and ethical review.

5. Ethics, public health and examination relevance

The strongest ethical distinction is between treating an existing patient through somatic editing and making heritable changes affecting future generations. Human embryo editing raises unresolved questions about safety, consent, disability discrimination and enhancement. The 2018 announcement of genome-edited babies in China attracted widespread condemnation. The World Health Organization's 2021 recommendations emphasised governance, oversight and international cooperation.

Access is another concern: technically successful therapies may require specialised laboratories, transplantation facilities and prolonged monitoring, placing them beyond many patients' reach. Agricultural assessment should consider food safety, biodiversity, seed access and local farming conditions rather than assuming every edited product has identical risks. For Prelims, remember that gene editing can delete, replace or regulate sequences, need not insert foreign DNA, and does not necessarily produce an inheritable change.

Previous year questions

No source-linked PYQ is available here yet. Use the practice questions below.

Practice questions